Gland Pharma Ltd.'s consolidated net profit fell 3% year-on-year in the fourth quarter of financial year 2025, missing analysts' estimates.
The drugmaker posted a bottom line of Rs 186 crore in the quarter ended March, according to an exchange filing on Tuesday. Analysts tracked by Bloomberg had a consensus estimate of Rs 233 crore.
Gland Pharma Q4 Highlights (Consolidated, YoY)
Revenue down 7.3% to Rs 1,425 crore versus Rs 1,537 crore (Bloomberg estimate: Rs 1,552 crore).
Ebitda down 0.7% to Rs 347.4 crore versus Rs 350 crore (Bloomberg estimate: Rs 376 crore).
Margin expands to 24.4% versus 22.8% (Bloomberg estimate: 24.2%).
Net profit down 3.1% to Rs 186 crore versus Rs 192 crore (Bloomberg estimate: Rs 233 crore).
The company's board recommended a final dividend of Rs 18 per equity share of a face value of Re 1 each for 2024–25. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the annual general meeting.
The record date to determine the shareholders eligible for the dividend payout for the financial year ended March 31 has been fixed as Aug. 14, according to an exchange filing.
Shares of Gland Pharma closed 1.35% higher at Rs 1,503.90 apiece on the NSE ahead of the results, compared to a 1.05% fall in the benchmark Nifty.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
